Featured Research

from universities, journals, and other organizations

Genomic tumor testing conducted

Date:
January 22, 2014
Source:
Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center
Summary:
Clinical laboratory experts and physicians achieved 100 percent accuracy using new gene sequencing equipment and panels to test for abnormal DNA in cancerous tumor cells, paving the way for routine genetic testing in personalizing cancer care

The NCCC Department of Pathology clinical laboratory is now able to perform genomic sequencing tests on patient tumor tissue.
Credit: Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center

Clinical laboratory experts and physicians at Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC) achieved 100 percent accuracy in testing for abnormal DNA in cancerous tumor cells with its new gene sequencing equipment and panels. The results, published in the journal Clinical Chemistry and Laboratory Medicine, confirm the precision of the test for routine patient care so physicians can tailor treatment to an individual person's DNA, improving the chances of a successful outcome.

Related Articles


"We evaluated next generation tools for gene sequencing in our clinical laboratory," said Gregory Tsongalis, PhD, director, molecular pathology. "The equipment and approach we are using is faster, more sensitive, and more reliable than previous approaches. It paves the way for routine genetic testing in personalizing cancer care here at the Norris Cotton Cancer Center."

The genomic sequencing test, called the Ion Torrent AmpliSeq Cancer Hotspot Panel, is often used in research settings. Now the clinically certified and accredited pathology laboratory at NCCC has put in place the ability to routinely perform this test on patient tumor tissue. The NCCC Department of Pathology clinical laboratory, where this testing is performed, is in compliance with the Clinical Laboratory Improvement Amendment (CLIA), which certifies laboratories to federal standards of quality, proficiency, and safety. It is also accredited by the College of American Pathologists, the gold standard in laboratory accreditation.

"This takes genetic sequencing information or molecular profiling of tumors and puts it into the hands of physicians treating patients today," said Tsongalis.

The laboratory has run over 400 patient samples, about 80 percent of which have identified genetic mutations. About 50 to 60 percent of the tests identify genetic mutations that change the course of treatment. Turnaround time for the test is one week to 10 days. Physicians and scientists test tumor samples from metastatic colon cancer, melanoma, gliomas, and non-small cell lung cancers. In the months to come, they will add testing for breast cancer, leukemia, and lymphoma. Patients' insurance companies reimburse for testing on known mutations as single-gene tests. The Norris Cotton Cancer laboratory, however, runs each sample against a wide panel of genetic mutations. The Cancer Hotspot Panel tests for mutations in 50 common cancer genes as part of a molecular profiling strategy to personalize therapy for an individual patient.

DNA is supposed to be well ordered, and it is considered damaged or mutated when there is an extra or missing section. Genetic mutations can be inherited or caused by environmental factors such as exposure to sunlight, cigarette smoke, or other carcinogens. Damaged DNA can send out the wrong messages to cells: telling them to multiply and grow in ways that can lead to tumors. By identifying the specific mutations in a tumor, physicians can chose medications that precisely target that location for treatment.


Story Source:

The above story is based on materials provided by Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gregory J. Tsongalis, Jason D. Peterson, Francine B. de Abreu, Christopher D. Tunkey, Torrey L. Gallagher, Linda D. Strausbaugh, Wendy A. Wells, Christopher I. Amos. Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clinical Chemistry and Laboratory Medicine, 2013; 0 (0): 1 DOI: 10.1515/cclm-2013-0883

Cite This Page:

Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center. "Genomic tumor testing conducted." ScienceDaily. ScienceDaily, 22 January 2014. <www.sciencedaily.com/releases/2014/01/140122153613.htm>.
Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center. (2014, January 22). Genomic tumor testing conducted. ScienceDaily. Retrieved March 30, 2015 from www.sciencedaily.com/releases/2014/01/140122153613.htm
Norris Cotton Cancer CenterDartmouth-Hitchcock Medical Center. "Genomic tumor testing conducted." ScienceDaily. www.sciencedaily.com/releases/2014/01/140122153613.htm (accessed March 30, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 30, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins